The Discovery and Structure of Insulin

Insulin was first isolated in 1921 by Frederick Banting and Charles Best at the University of Toronto, a breakthrough that transformed Type 1 diabetes from a fatal diagnosis into a manageable chronic condition. The discovery earned Banting and John Macleod the Nobel Prize in 1923, and within a year, commercial production using animal pancreases began. Chemically, insulin is a small protein hormone composed of 51 amino acids arranged in two chains — an A chain (21 amino acids) and a B chain (30 amino acids) — linked by two disulfide bonds. A third disulfide bond forms within the A chain. This precise three-dimensional structure, determined by X-ray crystallography in the 1960s, is essential for binding to the insulin receptor on target cells.

The human insulin gene (INS) is located on chromosome 11 and encodes a precursor called preproinsulin. After synthesis in the beta cell’s endoplasmic reticulum, preproinsulin is cleaved to proinsulin, which folds and is transported to the Golgi apparatus. There, proinsulin is packaged into secretory vesicles, where proteolytic enzymes (PC1/3 and PC2) remove the C-peptide to yield mature insulin. The C-peptide, once considered inert, is now known to have biological activities — such as enhancing nitric oxide production and protecting against diabetic nephropathy — and serves as a useful marker of residual beta cell function in people with diabetes.

The advent of recombinant DNA technology in the late 1970s allowed the production of human insulin in E. coli (Humulin, approved in 1982), ending reliance on animal sources. Further advances enabled the design of insulin analogs with altered pharmacokinetics: rapid‑acting insulins (lispro, aspart, glulisine) have amino acid substitutions that reduce self‑association, while long‑acting analogs (glargine, detemir, degludec) achieve protracted absorption through precipitation or albumin binding. These molecular modifications more closely mimic physiological insulin secretion, improving both glycemic control and safety.

Glucose‑Stimulated Insulin Secretion (GSIS)

The beta cell is exquisitely tuned to respond to changes in blood glucose concentration. The process of glucose‑stimulated insulin secretion involves a cascade of events that couples metabolic sensing to exocytosis. Here is a step‑by‑step breakdown:

  1. Glucose uptake: Glucose enters the beta cell primarily through the GLUT2 transporter (in rodents) or GLUT1/GLUT3 (in humans). The rate of uptake is proportional to extracellular glucose concentration, ensuring a rapid response to hyperglycemia.
  2. Glycolysis and ATP production: Inside the cell, glucose is phosphorylated by glucokinase (the rate‑limiting step of GSIS) and metabolized via glycolysis and the Krebs cycle, increasing the ATP/ADP ratio. Glucokinase acts as the glucose sensor — mutations in GCK cause MODY2, a form of monogenic diabetes.
  3. Closure of ATP‑sensitive potassium channels: The rise in ATP binds to and closes KATP channels (composed of Kir6.2 and SUR1 subunits). This reduces potassium efflux, causing the cell membrane to depolarize. Sulfonylurea drugs used in Type 2 diabetes work by binding to SUR1 and closing these channels.
  4. Voltage‑gated calcium channel activation: Depolarization opens L‑type calcium channels, allowing an influx of calcium ions into the cytosol. Additional calcium release from intracellular stores (ER) also contributes.
  5. Exocytosis of insulin granules: The elevated intracellular calcium concentration triggers the fusion of insulin‑containing vesicles with the plasma membrane, releasing insulin into the bloodstream. This process involves SNARE proteins (SNAP‑25, syntaxin, VAMP) and is modulated by amplifying pathways such as the KATP‑independent route involving glutamate or malonyl‑CoA.

This pathway is modulated by other nutrients (amino acids such as arginine and leucine), fatty acids, and hormones (incretins such as GLP‑1 and GIP). The incretin effect — whereby oral glucose elicits a greater insulin response than intravenous glucose — is mediated by gut hormones that potentiate GSIS. This is the basis for diabetes medications like DPP‑4 inhibitors and GLP‑1 receptor agonists. Interestingly, GSIS is pulsatile in nature, with insulin released in 5‑ to 15‑minute bursts, a pattern that enhances hepatic insulin action and is disrupted early in diabetes.

The Pancreatic Beta Cell and Its Microenvironment

Beta cells reside within the islets of Langerhans, clusters of endocrine cells scattered throughout the pancreas. Each human islet contains roughly 50–70% beta cells, along with alpha cells (glucagon), delta cells (somatostatin), PP cells (pancreatic polypeptide), and epsilon cells (ghrelin). The arrangement of these cell types is not random: beta cells occupy the core of the islet, while alpha and delta cells form a mantle. This spatial organization enables paracrine interactions that fine‑tune hormone secretion — for example, somatostatin from delta cells inhibits both insulin and glucagon release.

Beta cells are highly metabolic and rely on robust mitochondrial function to generate the ATP required for GSIS. They also express antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase) to protect against oxidative stress, but in Type 1 diabetes, this defense is overwhelmed by the inflammatory environment. The islet microvasculature is dense, with each islet receiving blood flow from one or two arterioles, allowing rapid diffusion of glucose and efficient delivery of secreted insulin to the portal vein and then to the liver. This intricate network is supported by pericytes and endothelial cells that also secrete trophic factors.

Interestingly, beta cells exhibit electrical activity similar to neurons. They fire action potentials in response to glucose, and their membrane potential oscillates, leading to pulsatile insulin secretion. This pulsatility is lost in early diabetes and in islet transplantation, contributing to impaired glycemic control. Recent research has also highlighted the role of beta cell heterogeneity — subpopulations with different maturation states, replication potentials, and susceptibility to stress may influence both normal function and disease progression.

Type 1 Diabetes: The Autoimmune Assault on Beta Cells

Type 1 diabetes results from a chronic, T‑cell‑mediated autoimmune attack that progressively destroys beta cells. This process often begins months or years before clinical symptoms appear, a phase known as the prediabetic or insulitic stage. At diagnosis, typically 70–90% of beta cells have already been lost. The disease is now staged by the American Diabetes Association: Stage 1 (autoantibodies, normoglycemia), Stage 2 (dysglycemia), and Stage 3 (symptomatic diabetes).

Genetic Susceptibility

The strongest genetic risk factors lie within the HLA region (specifically HLA‑DR3 and HLA‑DR4 haplotypes), which encodes molecules that present antigens to T cells. Variants in the INS gene (the insulin gene VNTR), CTLA‑4, PTPN22, and IL2RA also contribute. Genome‑wide association studies (GWAS) have identified over 60 loci, many involved in immune regulation. However, genetics alone does not explain disease onset — the concordance rate in identical twins is only about 50%, indicating a major role for environmental triggers.

Environmental Triggers

Proposed triggers include enteroviral infections (especially Coxsackie B viruses), early exposure to cow’s milk, vitamin D deficiency, and changes in the gut microbiome. The molecular mimicry hypothesis suggests that a viral protein resembles a beta cell antigen (such as GAD65), prompting cross‑reactive T cells to attack the pancreas. The Environmental Determinants of Diabetes in the Young (TEDDY) study is actively investigating these factors. Recent evidence also points to the role of the gut microbiome in modulating immune tolerance, with disrupted microbial communities linked to islet autoimmunity.

Immune Mechanisms

Autoreactive CD4+ and CD8+ T cells infiltrate the islets and destroy beta cells through direct cytotoxicity (perforin, granzymes, Fas‑FasL interactions) and by recruiting macrophages that secrete pro‑inflammatory cytokines (IL‑1β, TNF‑α, IFN‑γ). These cytokines further damage beta cells and upregulate surface molecules (e.g., MHC class I) that attract more immune cells. Regulatory T cells (Tregs) are unable to suppress this response, and B cells act as antigen‑presenting cells, producing autoantibodies. Autoantibodies against insulin, GAD65, IA‑2, and ZnT8 appear in the blood years before onset and serve as biomarkers for screening and prediction.

Once the beta cell mass falls below a critical threshold, insulin secretion becomes insufficient to maintain normoglycemia, leading to overt diabetes. The loss of beta cells is relentless, though some people retain low‑level C‑peptide secretion for many years — a phenomenon associated with fewer complications and a lower risk of hypoglycemia.

Clinical Manifestations and Diagnosis

The classic triad of Type 1 diabetes — polydipsia, polyuria, and weight loss — reflects the metabolic consequences of insulin deficiency. Without insulin, glucose cannot enter cells, so the body turns to fat and protein catabolism for energy. This leads to ketone body production, potentially culminating in diabetic ketoacidosis (DKA), a life‑threatening emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. Other symptoms include blurred vision (due to osmotic lens changes), fatigue, and recurrent infections (especially skin and genitourinary). In children, the onset can be abrupt, while adults may have a slower progression (latent autoimmune diabetes in adults, LADA), which often requires C‑peptide and antibody testing for correct classification.

Diagnosis is based on hyperglycemia criteria (fasting glucose ≥7.0 mmol/L, random glucose ≥11.1 mmol/L, or HbA1c ≥6.5%) plus the presence of one or more islet autoantibodies. Measurement of C‑peptide (low or undetectable) helps distinguish Type 1 from Type 2 diabetes, especially in adults. The ADA recommends screening at‑risk individuals (first‑degree relatives) for autoantibodies to identify early disease and potentially delay onset with immunotherapy. Screening for other autoimmune conditions (celiac disease, autoimmune thyroiditis) is also advised due to the increased prevalence.

Management of Type 1 Diabetes

The goal of management is to achieve near‑normal glycemia while avoiding hypoglycemia. This requires a combination of insulin replacement, glucose monitoring, nutrition, and physical activity — all adjusted to the individual’s lifestyle.

Insulin Therapy

Insulin is administered subcutaneously via multiple daily injections (MDI) or a continuous subcutaneous insulin infusion (insulin pump). Modern insulin analogs include:

  • Rapid‑acting insulins: Lispro, aspart, glulisine — onset ~10–15 minutes, peak ~1 hour, duration 3–4 hours. Used for meal coverage.
  • Short‑acting insulin: Regular human insulin — onset ~30 minutes, peak 2–3 hours, duration 5–8 hours.
  • Intermediate‑acting: NPH — peak 4–8 hours, duration 12–18 hours.
  • Long‑acting: Glargine, detemir, degludec — provide basal coverage with minimal peak; degludec has a duration >42 hours.
  • Concentrated formulations: U‑500 (regular), U‑300 (glargine) for severe insulin resistance.
  • Inhaled insulin: A rapid‑acting option (Afrezza) offers an alternative for some patients.

Insulin doses are calculated based on total daily dose (TDD), often 0.5–1.0 U/kg/day, divided into basal and prandial components. Pumps allow fine‑tuning with variable basal rates, bolus calculators, and temporary rates. Hybrid closed‑loop systems — such as Medtronic 780G, Tandem Control‑IQ, and Omnipod 5 — automatically adjust basal delivery and correct high glucose, achieving Time in Range (TIR) >70% in many users.

Glucose Monitoring

Self‑monitoring of blood glucose (SMBG) using fingerstick meters remains common, but continuous glucose monitors (CGMs) are increasingly adopted. CGMs measure interstitial glucose every few minutes, providing real‑time trends, alarms for hypo‑/hyperglycemia, and data for dose adjustments. Metrics such as TIR (target 70–180 mg/dL), Time Above Range, and the Glucose Management Indicator (GMI) have become standard. The hybrid closed‑loop system (artificial pancreas) integrates a CGM with an insulin pump and an algorithm to automate insulin delivery. The JDRF has funded pivotal clinical trials demonstrating improved glycemic outcomes with these systems, and recent advances include Bluetooth‑enabled pumps and smartphone‑based control.

Dietary and Lifestyle Considerations

Carbohydrate counting is essential for matching insulin doses to food intake, but fat and protein also affect postprandial glucose. Emphasis is placed on low glycemic index foods, fiber, healthy fats, and reduced refined sugars. Regular exercise improves insulin sensitivity but requires adjustments to prevent hypoglycemia — modifying bolus doses, consuming pre‑exercise snacks, and reducing basal rates. Consistent meal timing and sleep hygiene help stabilize glycemic patterns. Insulin‑to‑carbohydrate ratios and correction factors are individualized using advanced carbohydrate counting or simpler methods.

Psychosocial Support

Living with Type 1 diabetes can be burdensome. Diabetes distress, burnout, fear of hypoglycemia, and disordered eating are common. Multidisciplinary care involving endocrinologists, diabetes educators, dietitians, and mental health professionals improves outcomes and quality of life. Support groups and peer mentoring (e.g., through the Diabetes Daily community) also play a vital role.

Emerging Therapies and Research Frontiers

Research is accelerating toward prevention, preservation, and restoration of beta cell function. Key areas include:

Immunotherapy

Several agents have been tested to halt autoimmune attack. Teplizumab (an anti‑CD3 monoclonal antibody) was approved by the FDA in 2022 to delay the onset of clinical Type 1 diabetes in high‑risk individuals (Stage 2). Other approaches include CTLA‑4‑Ig (abatacept), anti‑CD20 (rituximab), and low‑dose interleukin‑2 therapy to boost Tregs. Antigen‑specific tolerance induction using oral insulin or GAD‑alum (Diamyd) is in clinical trials. Combination therapies that target multiple immune pathways may be more effective than monotherapy.

Beta Cell Replacement

Islet transplantation via the Edmonton Protocol can restore endogenous insulin production, but recipients require lifelong immunosuppression. Stem cell‑derived beta cells (from induced pluripotent stem cells or embryonic stem cells) are being tested in clinical trials. Vertex’s VX‑880 program has shown insulin independence in some patients using fully differentiated islet cells. Encapsulation devices — such as ViaCyte’s PEC‑Direct and PEC‑Encap — aim to protect transplanted cells from immune attack while allowing nutrient and insulin diffusion, with early clinical data promising.

Artificial Pancreas and Automated Insulin Delivery

As mentioned, hybrid closed‑loop systems are already available. Fully closed‑loop systems (no meal announcement) are in late‑phase trials. Advances in algorithm design (model predictive control, fuzzy logic), faster‑acting insulins, and dual‑hormone (insulin + glucagon) systems promise further improvement. The iLet bionic pancreas, which uses dosing based on initial weight and learning algorithms, has shown excellent TIR in trials.

Regenerative Medicine

Stimulating endogenous beta cell regeneration is a long‑term goal. Researchers are exploring transcription factors (Neurog3, Pdx1, MafA) to transdifferentiate pancreatic alpha or exocrine cells into beta cells. Partial reversals of diabetes in mice have been achieved, but translation to humans remains challenging. Additionally, the role of the gut microbiome is being investigated — fecal microbiota transplantation or specific pre/probiotics might modulate autoimmune activity.

For the latest updates, readers can consult resources like the PubMed database, the Diabetes Research Institute Foundation, and the ADA Research page.

Conclusion

Insulin production is a marvel of cellular engineering, finely tuned to maintain metabolic homeostasis. The autoimmune destruction of beta cells in Type 1 diabetes disrupts this system, leading to a lifelong need for exogenous insulin. Yet the scientific progress of the past century — from insulin discovery to closed‑loop technology and immune intervention — gives reason for optimism. The approval of teplizumab and the early success of stem cell therapies mark a new era of disease modification. By understanding the science behind insulin production and the mechanisms of beta cell loss, researchers and clinicians continue to refine treatments and inch closer to a cure. For those living with Type 1 diabetes, education, technology, and a supportive care team remain the pillars of successful management.